BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.Front Immunol. 2019;10:1848. [PMID: 31440242 DOI: 10.3389/fimmu.2019.01848] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Huang L, Zhao H, Shan M, Chen H, Xu B, He Y, Zhao Y, Liu Z, Chen J, Xu Q. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med 2022. [PMID: 35762456 DOI: 10.1002/cam4.4845] [Reference Citation Analysis]
2 Ferreira T, Kulkarni A, Bretscher C, Nazarov P, Hossain J, Ystaas L, Miletic H, Röth R, Niesler B, Marchini A. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells. Viruses 2022;14:1018. [DOI: 10.3390/v14051018] [Reference Citation Analysis]
3 de la Nava D, Selvi KM, Alonso MM. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Front Immunol 2022;13:866892. [PMID: 35493490 DOI: 10.3389/fimmu.2022.866892] [Reference Citation Analysis]
4 Firoz A, Ali HM, Rehman S, Rather IA. Gastric Cancer and Viruses: A Fine Line between Friend or Foe. Vaccines 2022;10:600. [DOI: 10.3390/vaccines10040600] [Reference Citation Analysis]
5 Jager MC, Tomlinson JE, Lopez-Astacio RA, Parrish CR, Van de Walle GR. Small but mighty: old and new parvoviruses of veterinary significance. Virol J 2021;18:210. [PMID: 34689822 DOI: 10.1186/s12985-021-01677-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
7 Jin S, Wang Q, Wu H, Pang D, Xu S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res 2021;9:71. [PMID: 34563270 DOI: 10.1186/s40364-021-00318-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Dias JNR, André AS, Aguiar SI, Gil S, Tavares L, Aires-da-Silva F. Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Front Vet Sci 2021;8:621758. [PMID: 34513964 DOI: 10.3389/fvets.2021.621758] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Huang FY, Wang JY, Dai SZ, Lin YY, Sun Y, Zhang L, Lu Z, Cao R, Tan GH. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity. J Immunother Cancer 2020;8:e000330. [PMID: 32759233 DOI: 10.1136/jitc-2019-000330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gao Y, Wu Y, Huan T, Wang X, Xu J, Xu Q, Yu F, Shi H. The application of oncolytic viruses in cancer therapy. Biotechnol Lett 2021;43:1945-54. [PMID: 34448096 DOI: 10.1007/s10529-021-03173-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ahmadi A, Ghaleh HE, Dorostkar R, Farzanehpour M, Bolandian M. Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review. CCTR 2021;17:173-8. [DOI: 10.2174/1573394716999201228215537] [Reference Citation Analysis]
12 Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, Eberle J, Ehrhardt A, Engeland CE, Fechner H, Geletneky K, Goepfert K, Holm PS, Kochanek S, Kreppel F, Krutzke L, Kühnel F, Lang KS, Marchini A, Moehler M, Mühlebach MD, Naumann U, Nawroth R, Nüesch J, Rommelaere J, Lauer UM, Ungerechts G. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses 2021;13:1420. [PMID: 34452286 DOI: 10.3390/v13081420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kodet O, Němejcova K, Strnadová K, Havlínová A, Dundr P, Krajsová I, Štork J, Smetana K Jr, Lacina L. The Abscopal Effect in the Era of Checkpoint Inhibitors. Int J Mol Sci 2021;22:7204. [PMID: 34281259 DOI: 10.3390/ijms22137204] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
14 Kulkarni A, Ferreira T, Bretscher C, Grewenig A, El-Andaloussi N, Bonifati S, Marttila T, Palissot V, Hossain JA, Azuaje F, Miletic H, Ystaas LAR, Golebiewska A, Niclou SP, Roeth R, Niesler B, Weiss A, Brino L, Marchini A. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry. Nat Commun 2021;12:3834. [PMID: 34158478 DOI: 10.1038/s41467-021-24034-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Senekal NS, Mahasa KJ, Eladdadi A, de Pillis L, Ouifki R. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model. Bull Math Biol 2021;83:75. [PMID: 34008149 DOI: 10.1007/s11538-021-00903-6] [Reference Citation Analysis]
16 Arora R, Malla WA, Tyagi A, Mahajan S, Sajjanar B, Tiwari AK. Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response. Front Oncol 2021;11:648873. [PMID: 34012915 DOI: 10.3389/fonc.2021.648873] [Reference Citation Analysis]
17 Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics 2021;13:547. [PMID: 33919827 DOI: 10.3390/pharmaceutics13040547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 64] [Article Influence: 2.0] [Reference Citation Analysis]
19 Angelova A, Ferreira T, Bretscher C, Rommelaere J, Marchini A. Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers. Cancers (Basel) 2021;13:342. [PMID: 33477757 DOI: 10.3390/cancers13020342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel) 2021;13:287. [PMID: 33466732 DOI: 10.3390/cancers13020287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
21 Pol JG, Workenhe ST, Konda P, Gujar S, Kroemer G. Cytokines in oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:4-27. [PMID: 33183957 DOI: 10.1016/j.cytogfr.2020.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
22 Forlani G, Shallak M, Celesti F, Accolla RS. Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. Cancers (Basel) 2020;12:E3181. [PMID: 33138029 DOI: 10.3390/cancers12113181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ferreira T, Kulkarni A, Bretscher C, Richter K, Ehrlich M, Marchini A. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis. Viruses 2020;12:E1199. [PMID: 33096814 DOI: 10.3390/v12101199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kuryk L, Bertinato L, Staniszewska M, Pancer K, Wieczorek M, Salmaso S, Caliceti P, Garofalo M. From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers (Basel) 2020;12:E3057. [PMID: 33092131 DOI: 10.3390/cancers12103057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
25 Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, Pockley AG, McArdle SEB. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Front Immunol 2020;11:582106. [PMID: 33178210 DOI: 10.3389/fimmu.2020.582106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
26 Hamada M, Yura Y. Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.Int J Mol Sci. 2020;21. [PMID: 32992948 DOI: 10.3390/ijms21197073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
27 Hu PY, Fan XM, Zhang YN, Wang SB, Wan WJ, Pan HY, Mou XZ. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol 2020;104:8231-42. [PMID: 32816087 DOI: 10.1007/s00253-020-10802-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Lathwal A, Kumar R, Raghava GP. Computer-aided designing of oncolytic viruses for overcoming translational challenges of cancer immunotherapy. Drug Discovery Today 2020;25:1198-205. [DOI: 10.1016/j.drudis.2020.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Rogovskii V. Modulation of Inflammation-Induced Tolerance in Cancer. Front Immunol 2020;11:1180. [PMID: 32676076 DOI: 10.3389/fimmu.2020.01180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Shanmugaraj B, Priya LB, Mahalakshmi B, Subbiah S, Hu R, Velmurugan BK, Baskaran R. Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy. Life Sciences 2020;250:117550. [DOI: 10.1016/j.lfs.2020.117550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
31 Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 2020;30:507-19. [PMID: 32467593 DOI: 10.1038/s41422-020-0337-2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 207] [Article Influence: 56.5] [Reference Citation Analysis]
32 Keshavarz M, Sabbaghi A, Miri SM, Rezaeyan A, Arjeini Y, Ghaemi A. Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot? Cancer Cell Int 2020;20:131. [PMID: 32336951 DOI: 10.1186/s12935-020-01219-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Hossain JA, Marchini A, Fehse B, Bjerkvig R, Miletic H. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. Neurooncol Adv 2020;2:vdaa013. [PMID: 32642680 DOI: 10.1093/noajnl/vdaa013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Lemos de Matos A, Franco LS, McFadden G. Oncolytic Viruses and the Immune System: The Dynamic Duo. Mol Ther Methods Clin Dev 2020;17:349-58. [PMID: 32071927 DOI: 10.1016/j.omtm.2020.01.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 69] [Article Influence: 22.5] [Reference Citation Analysis]